IASLC TTLC 2022 | Recent approvals in the NSCLC treatment landscape

Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, discusses novel agents in the non-small cell lung cancer (NSCLC) space. Whilst EGFR, ALK, and ROS1 have predominantly been targeted in NSCLC, there is an increasing number of newer targets including BRAF V600E, and MET exon 14 skipping mutations. EGFR exon 20 insertion mutations additionally have been resistant to existing tyrosine kinase inhibitors (TKIs) such as osimertinib, and the approval of mobocertinib and amivantamab will aim to improve the outcomes of patients with this subtype of EGFR-positive NSCLC. Dr Gentzler also highlights the approval of sotorasib, which will benefit patients with KRAS G12C-mutated NSCLC. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22).